Laboratory study shows succinyl-chitosan extended-release (XR) excipient could outperform commercially-available delivery technologies, says Spenser Pharmaceuticals.
Ricerca Biosciences say newly developed HPLC process offers drug firms API production that surpasses regulatory purity guidelines.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
Lonza buys viral-based biologics maker Vivante GMP Solutions to broaden custom manufacturing offering.
Transdermal delivery of a broader range of therapeutics could be possible using microdevice fabrication technology Vyteris inked a deal to access.
A fully-equipped disposable manufacturing facility has been added to CMC Biologic’s Seattle, WA site, as the first stage of a major expansion plan.
Mtech Bioprocess is to double scale-up square footage and staff to support Maryland, US biotechs’ non-GMP production work.
Cell penetration and pharmacodynamics boosting “stapled peptide” tech wins Aileron Therapeutics potential billion dollar protein drug development deal with Roche.
Parexel has collaborated with Stora Enso to add an integrated temperature recording system which can save up to 48 hours compared to traditional cold chain.
The US HHS is allocating $2bn (€1.6bn) to overhaul pandemic and bioterrorism capabilities through improvements to regulatory, developmental and manufacturing processes.
Midatech and MonoSol Rx have filed a provisional US patent application covering a nanoparticle film drug delivery system for administering biologics.
Improving safety and efficacy coupled with drug industry desire for “stronger” patents will drive growth of the biologics sector over the next five years, according to new research.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
Bioprocess purification chromatography tech wins BAC new deal after Swiss protein maker Octapharma licenses it for commercial-scale manufacture.